論文 2024年

2024年

英文

  1. Shiomi I, Makuuchi Y, Noura I, Kakuno S, Niki M, Kaimi Y, Ido K, Sakatoku K, Kuno M, Takakuwa T, Okamura H, NishiInvasivemoto M, NakashimaY, Nakamae M, Kakeya H, Kohashi K, Hino M, Nakamae H. Fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report. J Infect Chemother. 2024;Jun30(6):557-561. doi.org/10.1016/j.jiac.2023.12.002
  2. Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H. Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by Citrobacter freundii complex , Enterobacter cloacae complex, and Klebsiella aerogenes. J Chemother. 2024 Nov;36(7):521-531. doi: 10.1080/1120009X.2024.2323326. s
  3. Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagama S, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y. Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses. Sci Rep. 2024 Mar 27;14(1):7217. doi: 10.1038/s41598-024-57931-0.
  4. Imoto W, Ihara Y, Imai T, Tamato M, Ibuki T, Yamada K, Kaneko Y, Shintani A, Kakeya H. Evaluating the association of body mass index with COVID-19 severity and mortality using Japanese administrative claims data. J Infect Chemother, 2024 Oct;30(10):1054-1060. doi: 10.1016/j.jiac.2024.04.007.
  5. Kakeya H. Exploratory research for new diagnostic markers of mucormycosis. Med Mycol J, 65(2):29-32, 2024
  6. Yamada K, Kakeya H. Status and challenge of antifungal stewardship at the Osaka Metropolitan University Hospital. Med Mycol J, 65(2):33-38, 2024
  7. Imoto W, Imai T, Kawai R, Ihara Y, Nonomiya Y, Namikawa H, Yamada K, Yoshida H, Kaneko Y, Shintani A, Kakeya H. Incidence and Potential Risk Factors of Human Cytomegalovirus Infection in Patients with Severe and Critical Coronavirus disease 2019. J Infect Chemother . 2024 Jun 27:S1341-321X(24)00171-5. doi: 10.1016/j.jiac.2024.06.015. Online ahead of print.
  8. Kawaguchi H, Kakeya H, Nakagami-Yamaguchi E. Assessing the Impact of COVID-19 on Incident Reporting and Elucidating the Characteristics of Incident Reports for COVID-19 Patients at the Critical Care Center of a Tertiary-Care Teaching Hospital in Japan.Tohoku J Exp Med. 2024 Jan 10;262(1):5-12. doi: 10.1620/tjem.2023.J087. Epub 2023 Oct 19.
  9. Imoto W, Ihara Y, Imai T, Kawai R, Yamada K, Kaneko Y, Shintani A, Kakeya H. Incidence and risk factors for coronavirus disease 2019-associated pulmonary aspergillosis using administrative claims data. Mycoses. 2024 Aug;67(8):e13773. doi: 10.1111/myc.13773.
  10. Namikawa H, Oinuma KI, Kaneko Y, Kakeya H, Shuto T. Antimicrobial resistance in hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae: a systematic review and meta-analysis.Emerg Microbes Infect. 2025 Dec;14(1):2438657. doi: 10.1080/22221751.2024.2438657. Epub 2024 Dec 16.

和文

  1. 掛屋 弘. 予防接種の安全性と有効性. 今日の治療指針2024. 医学書院 2024, pp229-232.
  2. 掛屋 弘. 新型コロナのパンデミックを経験して〜これからの感染症研究への期待〜. バムサジャーナル, 36(2):3-11, 2024
  3. 柴多 渉, 掛屋 弘. ムーコル. 医学の歩み, 289(6):462-466, 2024
  4. 岡田 恵代, 野々瀬 由佳, 藤田 明子, 櫻井 紀宏, 中家 清隆, 山田 康一, 掛屋 弘. 蛍光塗料塗布面積解析ツールを用いた手指衛生手技の教育効果の検討 . 日本環境感染学会誌. 39(3) :70-75, 2024
  5. 掛屋 弘. 院内肺炎診療におけるタゾバクタム・セフトロザン（TAZ/CTLZ）の位置付け. 緑膿菌研究会会誌, 17-22, 2024
  6. 掛屋 弘. 抗菌薬使用最適化をめざした地域連携活動. 緑膿菌研究会会誌, 47-52, 2024
  7. 掛屋 弘.「臨床と微生物」と私の歩み. 真菌研究に携わってきて思うこと.「臨床と微生物」増刊号51:53-55, 2024
  8. 掛屋 弘. 私の治療−院内肺炎. 日本医事新報, 5246: 39-41, 2024
  9. 掛屋 弘. マスギャザリングイベントにおける感染対策−2025年大阪・関西万博に向けて−. Infection Control, メディカ出版, 33:4-9, 2024
  10. 掛屋 弘. 院内肺炎，医療・介護関連肺炎の診断治療と感染制御. 日本耳鼻咽喉科免疫アレルギー感染症学会誌 4(4): 177–181, 2024
論文バックナンバーに戻る
論文 2023年